SPDR S&P Biotech ETF

Key metrics

Fund snapshot

Verify current data at the official fund page. Metrics change.

Performance snapshot

The ~60-70% drawdown from mid-2021 through 2022 is the defining risk event for XBI. It demonstrates why this belongs in Dare, not Build.

What it is and why it matters

What it actually is

XBI is an equal-weighted ETF that tracks the S&P Biotechnology Select Industry Index. It holds approximately 150 biotech companies spanning the full market-cap spectrum — from micro-caps with single-product pipelines to large-cap names generating billions in annual revenue. Unlike cap-weighted funds, every holding gets roughly the same portfolio weight of about 0.67%.

The underlying index is constructed by S&P Dow Jones Indices and includes companies classified under the biotechnology industry sector. State Street Global Advisors (the SPDR brand) manages the fund. XBI has been trading since January 2006, giving it a track record that predates most of its holdings.

How equal weighting works in practice

In a cap-weighted fund like IBB, the largest companies can represent 10-15% of the portfolio individually. AbbVie, Amgen, and Gilead together make up roughly a third of IBB's weight — these are large pharmaceutical companies with established revenue streams, not pure-play biotech innovators.

In XBI, that same concentration doesn't exist. Every company gets approximately equal weight regardless of market capitalization. A small biotech with one drug in Phase 3 trials and a market cap of $2 billion has the same portfolio impact as a large-cap company generating $5 billion in annual revenue.

This is not a minor structural detail — it's the entire investment thesis. Equal weighting means XBI gives genuine representation to the companies most likely to produce asymmetric outcomes: FDA approvals, breakthrough clinical data, and acquisition targets. It also means those same events can devastate the fund when things go wrong.

FDA binary events explained

A single FDA decision — approval or rejection of a drug application — can move an individual biotech stock 50-100% in a single day. In XBI, because each holding has roughly equal weight, a cluster of positive FDA decisions across multiple small holdings can meaningfully lift the entire fund in a short period.

The reverse is equally true. When the FDA rejects applications or clinical trials fail — which happened dramatically during the 2021-2022 rate-hike cycle — XBI can drop 60-70% from peak to trough. This isn't a bug; it's what makes XBI a dare rather than a sector fund.

The key insight: equal weighting transforms individual binary events into portfolio-level outcomes. That's asymmetric upside in its purest form — and the reason this belongs in Dare, not Build.

Why that matters for the Dare slot

The Dare slot needs an asset with genuine asymmetric upside — something where a small allocation can produce outsized portfolio impact if your thesis plays out. XBI delivers exactly that through equal-weighted exposure to ~150 biotech companies, each carrying its own set of binary catalysts.

This is not a replacement for your Core Three — it's a complement. The Dare slot exists precisely because the Bogleheads framework leaves no room for conviction bets on things like FDA-driven biotech outcomes. XBI fills that gap cleanly and transparently.

The real tradeoff

You're paying 0.35% annually to hold a basket of companies where individual positions can swing 50-100% on single-day events, the fund itself has experienced 60-70% drawdowns, and the yield is essentially zero. In a biotech bull market, XBI investors will look like visionaries. In a rate-hike cycle or regulatory crackdown, they'll watch their Dare allocation shrink dramatically — and the Frame's 10% cap is what keeps it from becoming catastrophic.

The equal-weighting edge

This is the single most important concept to understand about XBI, so it gets its own section.

In plain terms

Imagine a portfolio with 150 companies. In an equal-weighted fund like XBI, each company gets roughly 0.67% of the total portfolio — no matter whether it's worth $2 billion or $200 billion on the open market.

In a cap-weighted fund like IBB, the largest companies dominate. The top 10 holdings might represent 40-50% of the entire fund. The smallest holdings get fractions of a percent — effectively zero impact on performance.

What this means for returns

In biotech bull markets: Small-cap companies tend to outperform large-caps because they have more room to grow and are more sensitive to positive catalysts. Equal weighting captures this tailwind — XBI tends to outperform cap-weighted peers during biotech rallies.

In bear markets or rate-hike cycles: Small-cap companies get hit hardest because they're most sensitive to discount rate changes and have the least revenue cushion. Equal weighting means you can't hide behind large-cap stability — XBI falls with its smallest holdings just as much as its largest.

The asymmetric outcome: If several small holdings get FDA approvals or acquisition offers, each could move 50-100% and meaningfully lift the entire fund. That's the asymmetric upside. But if those same companies face rejections or trial failures, the damage is equally concentrated.

XBI vs IBB: a concrete example

If AbbVie (a large pharmaceutical company) rises 10%, it might lift IBB by 1-2% because AbbVie represents roughly 10-15% of the fund. In XBI, AbbVie's weight is closer to 0.67% — its movement barely registers.

Conversely, if a $3 billion biotech with one drug in Phase 3 gets FDA approval and jumps 80%, it lifts XBI by roughly 0.54% (0.67% × 80%). In IBB, that same company might represent less than 0.1% of the fund — its 80% move is invisible.

This is why XBI is the actual dare and IBB is large pharma with a biotech label. XBI gives smaller companies real representation; IBB is dominated by established pharmaceutical giants.

Cost analysis

Expense ratio in context

At 0.35%, XBI's expense ratio is moderate for an actively managed thematic ETF but reasonable for a passively managed equal-weighted fund. On a $10,000 position, that's $35 per year. On $50,000, it's $175.

The real cost of XBI isn't the expense ratio — it's the volatility drag from holding ~150 companies where individual positions can swing 50-100% on single-day events. The 0.35% fee is the only cost you can predict with certainty; everything else comes from market dynamics and FDA binary outcomes.

How it compares to alternatives

XBI sits between IBB and ARKG in cost. It's cheaper than the actively managed ARKG (0.75%) but slightly more expensive than IBB (0.45%). The expense ratio difference is marginal on a $10K position — $40 per year separates XBI from ARKG. What matters more is methodology: passive equal-weighted vs. active stock-picking.

Long-term compounding impact

Over 20 years, the 0.35% expense ratio on a $10,000 Dare position costs roughly $804 in total fees (assuming no price appreciation for simplicity). On $50,000 it's about $4,020. These numbers are trivial compared to what FDA binary events and biotech market cycles will do — but they're worth knowing because the expense ratio is the only cost you can predict with certainty.

XBI vs. the competition

XBI vs. IBB (iShares Nasdaq Biotechnology ETF)

This is the most important comparison for XBI, and it comes down to one word: weighting.

XBI is equal-weighted. Every one of its ~150 holdings gets roughly the same portfolio weight (~0.67%). A small biotech with a pending FDA decision has the same impact on performance as a large company generating billions in annual revenue. This gives smaller companies real representation and creates genuine asymmetric upside from binary events.

IBB is cap-weighted. It's dominated by AbbVie, Amgen, and Gilead — three large pharmaceutical companies that together represent roughly a third of the fund's weight. These are established revenue-generating businesses with dividend payments, not pure-play biotech innovators. IBB is large pharma with a biotech label.

If your thesis is biotech innovation and asymmetric upside from smaller companies, XBI is the right vehicle. If your thesis is defensive healthcare exposure with dividend-paying pharma giants, IBB (or XLV) is more appropriate. Neither is universally better — they serve different investment theses.

XBI vs. ARKG (ARK Genomic Revolution ETF)

Both funds target the genomics and biotech innovation space, but they achieve it through completely different approaches.

XBI is passive and equal-weighted. It holds ~150 companies across the entire biotech spectrum with no active stock-picking. The 0.35% expense ratio reflects its passive structure. ARKG is actively managed by Cathie Wood's team at ARK Invest, concentrating on a narrower genomics thesis (roughly 40 holdings) at 0.75% expense ratio — more than double XBI's cost.

ARKG's active management means it can concentrate in names the managers believe in most strongly. That concentration amplifies both upside and downside. ARKG has produced spectacular gains during genomics bull markets and devastating losses during drawdowns. It's a narrower, higher-conviction bet than XBI.

XBI is broader, cheaper, and more transparent. ARKG is narrower, more expensive, and depends on Cathie Wood's stock-picking ability. Both are legitimate Dare picks for different reasons — but ARKG adds active management risk on top of biotech volatility.

XBI vs. XLV (Health Care Select Sector SPDR Fund)

This comparison highlights why XBI belongs in Dare and XLV belongs nowhere near it.

XLV holds 60+ healthcare companies including Johnson & Johnson, UnitedHealth, Eli Lilly, and Pfizer. It's a broad healthcare sector fund with defensive characteristics, dividend income, and relatively low volatility compared to pure biotech. XLV is the kind of fund you'd hold in Build or even Park as part of a core allocation.

XBI holds ~150 biotech companies with equal weighting, no large-cap stability anchor, and exposure to FDA binary events that can move individual positions 50-100% daily. XLV is far less speculative than XBI in every measurable dimension — expense ratio, volatility, drawdown severity, yield.

If you want healthcare exposure without dare-level risk, XLV is the right fund. If you want biotech innovation with asymmetric upside and can tolerate real downside risk, XBI is the right fund. They're not substitutes; they serve fundamentally different purposes in a portfolio.

Verify current data with fund sponsors. Numbers change.

Who should own XBI

Investors who should consider it

The biotech conviction player. Someone who understands that FDA binary events create genuine asymmetric outcomes and wants a fund that captures those outcomes across ~150 names. They don't need to pick individual stocks — they just need to believe the category thesis plays out over time.

The equal-weighting believer. Investors who think cap-weighted funds systematically underweight the companies most likely to produce outsized returns. They understand that a $3 billion biotech with one Phase 3 read has more upside potential than a $200 billion pharma company — and want their portfolio to reflect that reality.

The Dare slot architect. Someone building the Five Fund Frame who wants healthcare exposure in their dare position without mixing it into their core allocation. XBI gives them biotech innovation with real asymmetric upside, bounded by the 10% Dare cap.

Investors who should look elsewhere

Defensive positioning seekers. If you want healthcare exposure that won't drop 60-70% in a rate-hike cycle, XLV or IBB are better options. XBI is not defensive — it's the opposite of defensive by design.

Income-focused investors. The ~0.1-0.3% yield on XBI is essentially zero. Most of its holdings are growth-stage biotechs that reinvest everything into R&D. If you need income from your portfolio, this isn't the fund for you.

Anyone uncomfortable with binary events. A single FDA rejection can move an individual XBI holding 50-100% in a day. When multiple holdings face rejections simultaneously (as happened in 2021-2022), the fund itself can drop dramatically. If that keeps you up at night, XBI is the wrong fund.

Risks and considerations

FDA binary event risk. A single FDA decision — approval or rejection of a drug application — can move an individual biotech stock 50-100% in a day. In XBI, because holdings are equal-weighted, clusters of negative FDA decisions across multiple small holdings can meaningfully damage the entire fund. This is not rare; it's the normal operating environment for biotech investing.

Rate sensitivity risk. Biotech companies — especially smaller ones with no revenue — are highly sensitive to interest rates. When rates rise, the present value of future cash flows drops dramatically, and small-cap biotechs get hit hardest. The 2021-2022 rate-hike cycle produced a ~60-70% drawdown in XBI. This is not an outlier; it's what happens when you hold speculative growth companies in a rising-rate environment.

Concentration risk (by event, not by name). While XBI holds ~150 names and appears diversified, the holdings are all exposed to the same regulatory catalysts. When the FDA slows drug approvals or changes its review standards, multiple XBI positions can be affected simultaneously. This is diversification across companies but not across risk factors.

Liquidity risk (for individual holdings). While XBI itself trades ~10-15M shares daily with tight spreads, many of its underlying small-cap holdings trade far less volume. In stress scenarios, the fund's liquidity doesn't guarantee that every underlying position can be sold at fair value.

No yield cushion. Unlike stocks (which pay dividends) or bonds (which pay coupons), XBI's yield is ~0.1-0.3% — essentially nothing. In a long bear market, XBI investors watch their allocation shrink with no income to offset the decline. This makes holding through drawdowns psychologically harder than with dividend-paying funds.

How XBI fits in the Five Fund Frame

The Five Fund Frame assigns every dollar one of five jobs. XBI's job is simple: provide asymmetric upside exposure through equal-weighted biotech companies, bounded by the 10% Dare cap. It doesn't replace the Core Three (Park + Earn + Build). It sits on top as the optional fifth position.

The rules for Dare are strict. Never exceed 10% of your portfolio. Hold one fund, not a basket of speculative positions. Pick something you genuinely believe in — nobody should own XBI because a website told them to. The conviction has to be yours, and it has to survive the moment your allocation drops 40% in a month.

Starting points, not personalized advice. Adjust to your situation.